TERN Stock Summary and Trading Ideas (Terns Pharmaceuticals | NASDAQ:TERN)

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs.

Terns Pharmaceuticals trades on the NASDAQ stock market under the symbol TERN.

As of June 5, 2026, TERN stock price was flat at $52.95 with million shares trading.

TERN has a beta of -1.36, meaning it tends to be less sensitive to market movements. TERN has a correlation of 0.03 to the broad based SPY ETF.

TERN has a market cap of $6.11 billion. This is considered a Mid Cap stock.

In the last 3 years, TERN traded as high as $53.19 and as low as $1.87.

The top ETF exchange traded funds that TERN belongs to (by Net Assets): VTI, VXF, VTWO, VHT, VTWV.

TERN has outperformed the market in the last year with a price return of +1395.8% while the SPY ETF gained +25.6%. TERN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +26.1% and 0.0%, respectively, while the SPY returned +8.5% and -1.1%, respectively.

TERN support price is $52.95 and resistance is $52.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TERN shares will trade within this expected range on the day.